Keratolyten

Keratolyten is the name used in dermatology literature to describe a hypothetical keratolytic agent—a substance intended to soften and break down keratin in the outer skin layer, the stratum corneum. The name combines kerato- (keratin) and -lyten (dissolve). It is not a recognized commercial drug.

In theoretical descriptions, Keratolyten is described as acting on the keratinocyte outer layer by disrupting the disulfide bonds and keratin filament network, thereby reducing corneocyte cohesion and accelerating desquamation. Some accounts also propose enzymatic activity on keratin, but no experimental consensus exists.

Proposed clinical use includes the management of hyperkeratotic conditions such as calluses, corns, plantar keratoderma, ichthyosis, and some intractable warts. It is typically considered for topical administration in creams, gels, or solutions, with the exact formulation described only in speculative sources.

Because Keratolyten is not an approved or widely studied compound, there are no established dosing regimens or safety profiles. Potential adverse effects suggested in fictional or speculative contexts include skin irritation, dermatitis, and sensitization. As with other keratolytics, use would require medical supervision, particularly in sensitive skin or mucosal areas and during pregnancy.

In real-world dermatology, keratolysis is achieved with established agents such as salicylic acid, urea, lactic acid, sulfur, and retinoids. Keratolyten remains a theoretical construct or fictional example used to illustrate keratolytic mechanisms in educational or speculative texts.